A CASE OF EFFECTIVE ANTICOAGULANT THERAPY IN A PATIENT WITH CORONARY HEART DISEASE, CHRONIC HEART FAILURE, ATRIAL FIBRILLATION, AND LEFT VENTRICULAR THROMBOSIS

Objective: to describe effective treatment in a patient with stent thromboses and a left ventricular (LV) thrombus resistant to therapy with the novel anticoagulants clopidogrel and prasugrel.
Materials and methods. Patient P.V., aged 53 years, was admitted to the Department of Cardiology with complaints of dyspnea, lower limb edema, general weakness, palpitation, reduced urine output, and elevated body temperature. His medical history showed myocardial infarction experienced three times, coronary stenting using 3 drug-eluting stents, and stent thromboses. Echocardiography (EchoCG) revealed a mobile thrombus with a total area of 11 cm2 in the area of chronic LV aneurysm.
Results. According to the data of EchoCG conducted over time, there was a decrease in thrombus sizes to 3.06 cm2 during rivaroxaban therapy, their subsequent increase up to 9.25 cm2 after anticoagulant therapy that was discontinued without permission, and final lysis of a LV thrombus following the intake of rivaroxaban 20 mg/day during one month.
Conclusion. LV thrombus lysis in the rivaroxaban-treated patient with post-infarction cardiosclerosis and stent thromboses resistant to therapy with clopidogrel and prasugrel was described in this case.

1. Lip G.Y., Piotrponikowski P., Andreotti F. et al. Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm: an executive summary of a joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. Thromb Haemost 2012; 108(6):1009–22.

2. Lee G.Y., Song Y.B., Hahn J.Y. et al. Anticoagulation in ischemic left ventricular aneurysm. Mayo Clin Proc 2015;90(4):441–9.

3. Cregler L.L. Antithrombotic therapy in left ventricular thrombosis and systemic embolism. Am Heart J 1992;123(4 Pt 2):1110–4.

4. Ray S. Clopidogrel resistance: the way forward. Indian Heart J 2014;66(5):530–4.

5. del Castillo-Carnevali H., Barrios Alonso V., Zamorano Gómez J.L. Antiplatelet therapy: resistance to traditional antiaggregation drugs and role of new antiplatelet agents. Med Clin (Barc) 2014;143(5):222–9.

6. Uzun F., Biyik I., Akturk I.F. et al. Antiplatelet resistance and the role of associated variables in stable patients treated with stenting. Postepy Kardiol Interwencyjnej 2015;11(1):19–25.

7. Oikonomou E., Papageorqiou N., Papaioannou S. et al. Genetic testing and antiplatelet treatment: Still way to go? Int J Cardiol 2015;187:63–5.

8. Kastrati A. New anti-platelet agents: the end of resistance? Thromb Res 2012;130 Suppl 1: S53–5.

9. Ahmad S., Storey R.F. Development and clinical use of prasugrel and ticagrelor. Curr Pharm Des 2012;18(33):5240–60.

10. Varenhorst C., James S. Which antiplatelet agent for whom? Which patient populations benefit most from novel antiplatelet agents (ticagrelor, prasugrel)? Curr Cardiol Rep 2012;14(4):486–92.

11. Metzqer A., Nagaraj T. New Oral Anticoagulants: Clinical Parameters and Uses in Practice. Consult Pharm 2015; 30(6):329–45.

12. Nakasuka K., Ito S., Noda T. et al. Resolution of left ventricular thrombus secondary to tachycardia-induced heart failure with rivaroxaban. Case Rep Med 2014;2014:814524.

13. Mega J.L., Braunwald E., Wiviott S.D. et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012;366(1):9–19.